EUVIMEDEUVIMED entdecken
Crossref

Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma

Hitomi Takada, Koji Yamashita, Leona Osawa, Yasuyuki Komiyama, Natsuko Nakakuki, Masaru Muraoka, Yuichiro Suzuki, Mitsuaki Sato, Shinichi Takano, Mitsuharu Fukasawa, Tatsuya Yamaguchi, Shinya Maekawa und 3 weitere

Oncology · 2023

DOI: 10.1159/000531111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2023. Verfasst von Hitomi Takada und 14 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Kidney Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Several studies have reported kidney injury caused by immune checkpoint inhibitors, and proteinuria caused by vascular endothelial growth factor inhibitors for unresectable hepatocellular carcinoma (u-HCC). We investigated the relationship between renal function and prognosis in patients with u-HCC receiving atezolizumab and bevacizumab (AB) and lenvatinib (LEN) therapy.

Methods

Fifty-one patients who received AB and 50 patients who received LEN therapy were included. We analyzed prognostic factors related to the overall survival (OS), and characteristics related to renal function.

Results

In patients with AB therapy, OS was shorter in patients with baseline proteinuria of 1+ or higher, as assessed by urine dipstick test, compared to those with –/± (p = 0.024). There were many cases with two or more drugs with a high risk of renal dysfunction (p = 0.019) in patients with 1+ or higher. Furthermore, OS was shorter in the group with estimated glomerular filtration rate (eGFR) grade deterioration without urinary protein-creatinine ratio (UPCR) of 2 g/g·Cre or higher than in the other groups (p = 0.027). In the group where eGFR worsened without an increase in UPCR, there were many cases with a daily salt intake of 10 g or more (p = 0.027), three or more drugs with a high risk of renal dysfunction (p = 0.021), and a history of arteriosclerosis (p = 0.021). On the other hand, in patients with LEN therapy, OS tends to be shorter in patients with proteinuria of ± or higher, compared to those without (p = 0.074). There were many cases with a daily salt intake of 10 g or more in patients with ± or higher (p = 0.002).

Conclusion

In patients receiving AB and LEN therapy, baseline proteinuria was associated with OS. Renal function deterioration without proteinuria was associated with a poor prognosis in AB therapy. Excessive salt intake, preexisting atherosclerotic disease, and drug with a high risk of renal dysfunction were risk factors for renal deterioration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsKidney DiseasesHumansBevacizumabSodium Chloride, DietaryVascular Endothelial Growth Factor APrognosisKidneyPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AtezolizumabBevacizumabHepatocellular carcinomaLenvatinibRenal function

Substanzen

BevacizumabSodium Chloride, DietaryVascular Endothelial Growth Factor AlenvatinibPhenylurea CompoundsQuinolinesatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Gastroenterology and Hepatology Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
  • Nephrology Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Zitieren

APA

Takada, H., Yamashita, K., Osawa, L., Komiyama, Y., Nakakuki, N., Muraoka, M., Suzuki, Y., Sato, M., Takano, S., Fukasawa, M., Yamaguchi, T., Maekawa, S., Takahashi, K., Uchimura, K., & Enomoto, N. (2023). Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma. Oncology. https://doi.org/10.1159/000531111

Vancouver

Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, et al. Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma. Oncology. 2023. doi:10.1159/000531111

BibTeX
@article{Takada2023,
  author = {Takada, Hitomi and Yamashita, Koji and Osawa, Leona and Komiyama, Yasuyuki and Nakakuki, Natsuko and Muraoka, Masaru and Suzuki, Yuichiro and Sato, Mitsuaki and Takano, Shinichi and Fukasawa, Mitsuharu and Yamaguchi, Tatsuya and Maekawa, Shinya and Takahashi, Kazuya and Uchimura, Kohei and Enomoto, Nobuyuki},
  title = {Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma},
  journal = {Oncology},
  year = {2023},
  doi = {10.1159/000531111}
}
Kostenlos starten →